A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Interventions: Drug: ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle

Brief Summary: This is an open-label, single arm, and registered study of ATG-010 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Detailed Description: This is an open-label, single arm, and registered study. About 60 patients with relapsed/refractory DLBCL plan to be enrolled in about 10 study sites of the study. It is planned that at least 50% (\~30 patients) will have the GCB subtype of DLBCL. Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle. Patients should remain on the study treatment of ATG-010, until either PD or occurrence of unacceptable toxicity.

Recruitment & Eligibility

Inclusion Criteria

The patient must provide informed consent form (ICF) prior to the first screening procedure.
Age ≥18 years.
ECOG performance status of ≤ 2.
Patients should have estimated life expectancy of >3 months at study entry.
Previously treated, pathologically confirmed de novo DLBCL, or DLBCL transformed from previously diagnosed indolent lymphoma (e.g., follicular lymphoma).
Patients must have received at least 2 but no more than 5 previous systemic regimens for the treatment of their de novo or transformed DLBCL.
Documented clinical or radiographic evidence of progressive DLBCL prior to dosing.
Patients must have measurable disease per the revised criteria for response assessment of lymphoma (Cheson, 2014).
Patients must not be eligible for high-dose chemotherapy with autologous stem cell transplantation rescue.

Exclusion Criteria

Patients who are pregnant or lactating.
DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma, composite lymphoma (Hodgkin's lymphoma +NHL), or DLBCL transformed from diseases other than indolent NHL or Richter's.
Primary mediastinal (thymic) large B-cell lymphoma.
Known central nervous system lymphoma or meningeal involvement.
Patients whose most recent systemic anticancer therapy include radiation, chemotherapy, immunotherapy, radio-immunotherapy, or any other anticancer therapy other than glucocorticoids < 6 weeks prior to first dose of study drug.
Patients who have not recovered to Grade ≤ 1 clinically significant adverse events, or to their baseline, from their most recent systemic anti-DLBCL therapy.
Patients with active graft-versus-host disease after allogeneic stem cell transplantation. At least 4 months must have elapsed since completion of allogeneic stem cell transplantation.
Major surgery within 2 weeks of first dose of study treatment of ATG-010.
Any life-threatening illness, medical condition or organ system dysfunction which, in the Investigator's opinion, could compromise the patient's safety.
Active hepatitis B virus or hepatitis C virus infection.
Known human immunodeficiency virus infection.

Arm && Interventions

Group	Intervention	Description
ATG-010	ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle	Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010.

Primary Outcome Measures

Name	Time	Method
ORR	12 months	ORR is defined as the proportion of patients who achieve either complete response (CR) or partial response (PR) according to the revised criteria for response assessment of lymphoma (2014 Lugano criteria: A complete metabolic response requires Score 1, 2, or 3 with or without a residual mass on 5PS(5-point scale using PET-CT). A PR requires a decrease by more than 50% in the sum of the product of the perpendicular diameters of up to six representative nodes or extranodal lesions.)

Secondary Outcome Measures

Name	Time	Method
PFS	12 months	PFS is defined as the duration from start of selinexor treatment to time of central imaging laboratory determined PD (based on 2014 Lugano criteria: Progressive metabolic disease requires Score 4 or 5 with an increase in intensity of uptake from baseline. Progressive disease by CT criteria only requires an increase in the PPDs of a single node by ≥ 50%.)or death from any cause, whichever occurs first.

Locations (18): Peking University Third Hospital
🇨🇳
Beijing, Beijing, China
Sun Yat-Sen University Cancer Center
🇨🇳
Guangzhou, Guangdong, China
The Second Hospital of Dalian Medical University
🇨🇳
Dalian, Liaoning, China
Henan Cancer Hospital
🇨🇳
Zhengzhou, Henan, China
Beijing Cancer Hospital
🇨🇳
Beijing, Beijing, China
Anhui Province Cancer Hospital
🇨🇳
Hefei, Anhui, China
Harbin Medical University Cancer Hospital
🇨🇳
Harbin, Heilongjiang, China
Chongqing Universtity Cancer Hospital
🇨🇳
Chongqing, Chongqing, China
Hubei Cancer Hospital
🇨🇳
Wuhan, Hubei, China
Wuhan Union Hospital
🇨🇳
Wuhan, Hubei, China
The First Bethune Hospital of Jilin University
🇨🇳
Chang chun, Jilin, China
West China Hospital of Sichuan University
🇨🇳
Chengdu, Sichuan, China
Hunan Cancer Hospital
🇨🇳
Changsha, Hunan, China
The First Affilate Hospital with Nanjing Medical University
🇨🇳
Nanjing, Jiangsu, China
Fudan University Shanghai Cancer Center
🇨🇳
Shanghai, Shanghai, China
Tianjin blood research institute
🇨🇳
Tianjin, Tianjin, China
Tianjin Medical University Cancer Institute & Hospital
🇨🇳
Tianjin, Tianjin, China
Cancer Hospital of the University of the Chinese Academy of Sciences
🇨🇳
Hangzhou, Zhejiang, China